Clinical trials: Acute Ischemic Stroke AIS, active
Acute Ischemic Stroke AIS, Stroke Acute
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design.
- Conditions
- Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
- Trial name
- ACT-WHEN (NCT06320431)
- Testing
- Tenecteplase
- Where
- 24 sites in Australia, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke AIS
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke
Although mechanical thrombectomy or thrombolytic therapy for large vessels can achieve a revascularization rate (TICI ≥2b) of over 90%, 30-50% of patients still exhibit poor functional outcomes.
- Trial name
- NCT07003386
- Testing
- Galantamine, Standard treatment for acute ischemic stroke
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Acute Ischemic Stroke
Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)
The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke.
- Trial name
- NCT06696703
- Testing
- Human urinary kininogenase(HUK)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.
Acute Ischemic Stroke, Active Cancer
Acute Ischemic Stroke in Patients With Active Cancer
The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke.
- Trial name
- CAT-AIS (NCT07819526)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Osaka University
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 5 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
AIS
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
- Trial name
- NCT07520565
- Testing
- BXOS110
- Where
- 9 sites in China
- Volunteers
- 1,112 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Ischemic Stroke, Large Vessel Occlusion
Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke
The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.
- Trial name
- ARTEMIS (NCT07174505)
- Testing
- Mechanical Thrombectomy using the CONDA Stent Retriever
- Where
- 2 sites in Hungary, Spain
- Volunteers
- 50 people
- Sponsor
- Anaconda Biomed S.L.
Acute Ischemic Stroke (AIS)
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.
- Trial name
- AAPB (NCT06679998)
- Testing
- Single dose, AAPB by injection, intravenous drip., Multiple dosing, AAPB for injection, intravenous drip
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Stroke Acute, Acute Ischemic Stroke AIS
One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy
Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability.
- Conditions
- Stroke Acute, Acute Ischemic Stroke AIS, Hemorrhagic Stroke, Intracerebral
- Trial name
- GET-FAST (NCT07052045)
- Testing
- One Stop Management, Usual care management
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 390 people
- Sponsor
- Prof. Dr. Jan Liman
Acute Ischemic Stroke (AIS), Pediatric Stroke
Prospective Registry of Acute Ischemic Stroke in Children Under 18 Years Old in China
This observational study aims to investigate the real-world effectiveness and safety of different treatment strategies for acute ischemic stroke (AIS) in Chinese children under 18 years of age.
- Trial name
- NCT07550257
- Testing
- Standard Clinical Management
- Volunteers
- 1,000 people
- Sponsor
- Gansu Provincial Maternal and Child Health Care Hospital
Acute Ischemic Stroke AIS
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous…
- Trial name
- NCT07084012
- Testing
- hUC-MSCs treatment (high dose), hUC-MSCs treatment (low dose)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)
- Trial name
- NCT07890298
- Testing
- LT3001 Drug Product
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Acute Ischemic Stroke AIS
Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke
Acute ischemic stroke is caused by reduced blood supply to the brain associated with neuroinflammation. This mechanism contributes to acute neuronal death and persists even after reopening of the closed vessel, with consequent…
- Trial name
- NCT06777680
- Testing
- co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg), Thrombectomy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedali Riuniti Trieste
Acute Ischemic Stroke From Large Vessel Occlusion, Endovascular Thrombectomy
Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO
The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.
- Trial name
- PROMOTE-EVT (NCT07042490)
- Testing
- Plasma adsorption, Endovascular Thrombectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yi Yang
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.